Biogen Bolsters Position In MS Now That Tecfidera Is A Blockbuster
This article was originally published in The Pink Sheet Daily
Executive Summary
The spec pharma’s latest MS offering surpasses $1 billion in sales as roll-out begins in Europe and focuses some of its resources toward its budding hemophilia franchise.